Literature DB >> 16354753

Functional genomics of membrane transporters in human populations.

Thomas J Urban1, Ronnie Sebro, Evan H Hurowitz, Maya K Leabman, Ilaria Badagnani, Leah L Lagpacan, Neil Risch, Kathleen M Giacomini.   

Abstract

Although considerable progress has been made toward characterizing human DNA sequence variation, there remains a deficiency in information on human phenotypic variation at the single-gene level. We systematically analyzed the function of all protein-altering variants of eleven membrane transporters in heterologous expression systems. Coding-region variants were identified by screening DNA from a large sample (n = 247-276) of ethnically diverse subjects. In total, we functionally analyzed 88 protein-altering variants. Fourteen percent of the polymorphic variants (defined as variants with allele frequencies > or =1% in at least one major ethnic group) had no activity or significantly reduced function. Decreased function variants had significantly lower allele frequencies and were more likely to alter evolutionarily conserved amino acid residues. However, variants at evolutionarily conserved positions with approximately normal activity in cellular assays were also at significantly lower allele frequencies, suggesting that some variants with apparently normal activity in biochemical assays may influence occult functions or quantitative degrees of function that are important in human fitness but not measured in these assays. For example, eight (14%) of the 58 variants for which we had measured the transport of at least two substrates showed substrate-specific defects in transport. These variants and the reduced function variants provide plausible candidates for disease susceptibility or variation in clinical drug response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354753      PMCID: PMC1361718          DOI: 10.1101/gr.4356206

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  40 in total

1.  Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis.

Authors:  M K Halushka; J B Fan; K Bentley; L Hsie; N Shen; A Weder; R Cooper; R Lipshutz; A Chakravarti
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

2.  Characterization of single-nucleotide polymorphisms in coding regions of human genes.

Authors:  M Cargill; D Altshuler; J Ireland; P Sklar; K Ardlie; N Patil; N Shaw; C R Lane; E P Lim; N Kalyanaraman; J Nemesh; L Ziaugra; L Friedland; A Rolfe; J Warrington; R Lipshutz; G Q Daley; E S Lander
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

3.  A frameshift mutation in MC4R associated with dominantly inherited human obesity.

Authors:  G S Yeo; I S Farooqi; S Aminian; D J Halsall; R G Stanhope; S O'Rahilly
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

4.  A frameshift mutation in human MC4R is associated with a dominant form of obesity.

Authors:  C Vaisse; K Clement; B Guy-Grand; P Froguel
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

Review 5.  Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine.

Authors:  O Lockridge
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

7.  Amino acid difference formula to help explain protein evolution.

Authors:  R Grantham
Journal:  Science       Date:  1974-09-06       Impact factor: 47.728

8.  Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations.

Authors:  Jennifer H Gray; Lara M Mangravite; Ryan P Owen; Thomas J Urban; Wendy Chan; Elaine J Carlson; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

Review 9.  GLUT1 deficiency and other glucose transporter diseases.

Authors:  Juan M Pascual; Dong Wang; Beatriz Lecumberri; Hong Yang; Xia Mao; Ru Yang; Darryl C De Vivo
Journal:  Eur J Endocrinol       Date:  2004-05       Impact factor: 6.664

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  24 in total

Review 1.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

3.  Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.

Authors:  Ningwu Huang; Vishal Agrawal; Kathleen M Giacomini; Walter L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

Review 4.  Genetic variation in drug transporters in ethnic populations.

Authors:  C D Cropp; S W Yee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2008-06-04       Impact factor: 6.875

5.  Pharmacogenomics of membrane transporters: past, present and future.

Authors:  Sook Wah Yee; Ligong Chen; Kathleen M Giacomini
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 6.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

Review 7.  Creating and evaluating genetic tests predictive of drug response.

Authors:  Scott T Weiss; Howard L McLeod; David A Flockhart; M Eileen Dolan; Neal L Benowitz; Julie A Johnson; Mark J Ratain; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2008-06-20       Impact factor: 84.694

8.  Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.

Authors:  Ying Chen; Kristen Teranishi; Shuanglian Li; Sook Wah Yee; Stephanie Hesselson; Doug Stryke; Susan J Johns; Thomas E Ferrin; Pui Kwok; Kathleen M Giacomini
Journal:  Pharmacogenomics J       Date:  2009-01-27       Impact factor: 3.550

Review 9.  Trichloroethylene biotransformation and its role in mutagenicity, carcinogenicity and target organ toxicity.

Authors:  Lawrence H Lash; Weihsueh A Chiu; Kathryn Z Guyton; Ivan Rusyn
Journal:  Mutat Res Rev Mutat Res       Date:  2014 Oct-Dec       Impact factor: 5.657

10.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.